BioAffinity Technologies (BIAF) said the Australian patent office accepted its patent application for the method used in the CyPath Lung diagnostic test for predicting lung cancer.
The Australian patent, expected to be issued in three months, will expire in 2042 and will be the second patent for the CyPath Lung test, the company said Wednesday in a statement.
Price: 0.68, Change: +0.01, Percent Change: +2.09
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.